The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

PubChem1295     pyridine-3,4-diamine

Synonyms: SureCN21273, D7148_ALDRICH, CHEMBL354077, SC10, AG-B-95757, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of 3,4-DAP


Psychiatry related information on 3,4-DAP


High impact information on 3,4-DAP


Chemical compound and disease context of 3,4-DAP


Biological context of 3,4-DAP


Anatomical context of 3,4-DAP


Associations of 3,4-DAP with other chemical compounds


Gene context of 3,4-DAP

  • Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4-diaminopyridine [30].
  • The potassium-channel blocker, 3,4-diaminopyridine, increased force of dy/dy sternohyoid muscle during twitch and 25-Hz contractions by 148 +/- 20% (p < 0.00001) and 109 +/- 18% (p < 0.00002), respectively [31].
  • 4. Similar prolongation of slow Ca2+ current was effected by 3,4-diaminopyridine, whereas addition of apamin, aprotinin or phospholipase A2 left the signals unchanged [32].
  • 4. At control endplates, in vitro block of presynaptic K+ channels by 5 microM 3,4-diaminopyridine did increase the quantal content to a level which was similar to that found in endplates of alpha BTX-treated rats but also induced a broadening of EPPs, which was not found at endplates after alpha BTX treatment [33].
  • In contrast, exposure to 3,4-diaminopyridine (DAP; which similarly affects transmitter release by partially blocking potassium channels, altering the shape of the presynaptic action potential, and indirectly increasing calcium entry) increased paired-pulse facilitation (by 23%) [34].

Analytical, diagnostic and therapeutic context of 3,4-DAP


  1. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. McEvoy, K.M., Windebank, A.J., Daube, J.R., Low, P.A. N. Engl. J. Med. (1989) [Pubmed]
  2. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. Bever, C.T., Leslie, J., Camenga, D.L., Panitch, H.S., Johnson, K.P. Ann. Neurol. (1990) [Pubmed]
  3. 3,4-Diaminopyridine in demyelinating peripheral neuropathies. Tamura, R., Mano, Y., Takayanagi, T., Mayer, R.F. Ann. Neurol. (1994) [Pubmed]
  4. Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine. Smith, A.G., Wald, J. Neurology (1996) [Pubmed]
  5. Selective improvement of aged rat short-term spatial memory by 3,4-diaminopyridine. Barnes, C.A., Eppich, C., Rao, G. Neurobiol. Aging (1989) [Pubmed]
  6. The effects of some K(+) channel blockers on scopolamine- or electroconvulsive shock-induced amnesia in mice. Inan, S.Y., Aksu, F., Baysal, F. Eur. J. Pharmacol. (2000) [Pubmed]
  7. Comparison of DuP 996, with physostigmine, THA and 3,4-DAP on hypoxia-induced amnesia in rats. DeNoble, V.J., DeNoble, K.F., Spencer, K.R., Johnson, L.C., Cook, L., Myers, M.J., Scribner, R.M. Pharmacol. Biochem. Behav. (1990) [Pubmed]
  8. Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine. Mainero, C., Inghilleri, M., Pantano, P., Conte, A., Lenzi, D., Frasca, V., Bozzao, L., Pozzilli, C. Neurology (2004) [Pubmed]
  9. Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies. Bergin, P.S., Miller, D.H., Hirsch, N.P., Murray, N.M. Ann. Neurol. (1993) [Pubmed]
  10. Calcium-activated potassium channel SK1- and IK1-like immunoreactivity in injured human sensory neurones and its regulation by neurotrophic factors. Boettger, M.K., Till, S., Chen, M.X., Anand, U., Otto, W.R., Plumpton, C., Trezise, D.J., Tate, S.N., Bountra, C., Coward, K., Birch, R., Anand, P. Brain (2002) [Pubmed]
  11. Aging and 3,4-diaminopyridine alter synaptosomal calcium uptake. Peterson, C., Gibson, G.E. J. Biol. Chem. (1983) [Pubmed]
  12. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Polman, C.H., Bertelsmann, F.W., de Waal, R., van Diemen, H.A., Uitdehaag, B.M., van Loenen, A.C., Koetsier, J.C. Arch. Neurol. (1994) [Pubmed]
  13. 3,4-diaminopyridine alters acetylcholine metabolism and behavior during hypoxia. Peterson, C., Gibson, G.E. J. Pharmacol. Exp. Ther. (1982) [Pubmed]
  14. Use of pharmacologic antagonists to deduce commonalities of biologic activity among clostridial neurotoxins. Simpson, L.L. J. Pharmacol. Exp. Ther. (1988) [Pubmed]
  15. Hemodynamic effects of 3,4-diaminopyridine in a swine model of verapamil toxicity. Plewa, M.C., Martin, T.G., Menegazzi, J.J., Seaberg, D.C., Wolfson, A.B. Annals of emergency medicine. (1994) [Pubmed]
  16. The relative potencies of cholinomimetics and muscarinic antagonists on the rat iris in vivo: effects of pH on potency of pirenzepine and telenzepine. Hagan, J.J., van der Heijden, B., Broekkamp, C.L. Naunyn Schmiedebergs Arch. Pharmacol. (1988) [Pubmed]
  17. Electrophysiologic and inotropic effects of K+-channel blockade in aged diaphragm. van LUNTEREN, E., Moyer, M. Am. J. Respir. Crit. Care Med. (1998) [Pubmed]
  18. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Judge, S.I., Bever, C.T. Pharmacol. Ther. (2006) [Pubmed]
  19. Stimulation-induced changes in [Ca2+] in lizard motor nerve terminals. David, G., Barrett, J.N., Barrett, E.F. J. Physiol. (Lond.) (1997) [Pubmed]
  20. The potassium conductance of the resting squid axon and its blockage by clinical concentrations of general anaesthetics. Haydon, D.A., Requena, J., Simon, A.J. J. Physiol. (Lond.) (1988) [Pubmed]
  21. Effects of apamin, quinine and neuromuscular blockers on calcium-activated potassium channels in guinea-pig hepatocytes. Cook, N.S., Haylett, D.G. J. Physiol. (Lond.) (1985) [Pubmed]
  22. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Lundh, H., Nilsson, O., Rosén, I. Neurology (1984) [Pubmed]
  23. Inhibition of redox cycling of methoxatin (PQQ), and of superoxide release by phagocytic white cells. Bishop, A., Paz, M.A., Gallop, P.M., Karnovsky, M.L. Free Radic. Biol. Med. (1995) [Pubmed]
  24. 3,4-diaminopyridine. A potent new potassium channel blocker. Kirsch, G.E., Narahashi, T. Biophys. J. (1978) [Pubmed]
  25. Synaptic transmission in low extracellular calcium is preserved by 3,4-diaminopyridine. Matsumoto, M., Riker, W.K. J. Pharmacol. Exp. Ther. (1983) [Pubmed]
  26. Respiratory muscle weakness in the Lambert-Eaton myasthenic syndrome. Laroche, C.M., Mier, A.K., Spiro, S.G., Newsom-Davis, J., Moxham, J., Green, M. Thorax (1989) [Pubmed]
  27. Membrane properties related to the firing behavior of zebrafish motoneurons. Buss, R.R., Bourque, C.W., Drapeau, P. J. Neurophysiol. (2003) [Pubmed]
  28. A role for potassium currents in the generation of the swimming motor pattern of Xenopus embryos. Wall, M.J., Dale, N. J. Neurophysiol. (1994) [Pubmed]
  29. Increased presynaptic protein kinase C activity and glutamate release in rats with a prenatally induced hippocampal lesion. Di Luca, M., Caputi, A., Cattabeni, F., De Graan, P.N., Gispen, W.H., Raiteri, M., Fassio, A., Schmid, G., Bonanno, G. Eur. J. Neurosci. (1997) [Pubmed]
  30. Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4-diaminopyridine. Banwell, B.L., Ohno, K., Sieb, J.P., Engel, A.G. Neuromuscul. Disord. (2004) [Pubmed]
  31. Sternohyoid muscle fatigue properties of dy/dy dystrophic mice, an animal model of merosin-deficient congenital muscular dystrophy. van Lunteren, E., Moyer, M. Pediatr. Res. (2003) [Pubmed]
  32. The actions of presynaptic snake toxins on membrane currents of mouse motor nerve terminals. Dreyer, F., Penner, R. J. Physiol. (Lond.) (1987) [Pubmed]
  33. The upregulation of acetylcholine release at endplates of alpha-bungarotoxin-treated rats: its dependency on calcium. Plomp, J.J., van Kempen, G.T., Molenaar, P.C. J. Physiol. (Lond.) (1994) [Pubmed]
  34. The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction. Cho, S., Meriney, S.D. Eur. J. Neurosci. (2006) [Pubmed]
  35. An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Sheean, G.L., Murray, N.M., Rothwell, J.C., Miller, D.H., Thompson, A.J. Brain (1998) [Pubmed]
  36. Functions of large conductance Ca2+-activated (BKCa), delayed rectifier (KV) and background K+ channels in the control of membrane potential in rabbit renal arcuate artery. Prior, H.M., Yates, M.S., Beech, D.J. J. Physiol. (Lond.) (1998) [Pubmed]
  37. Release of acetylcholine from tissue slices of the rat nucleus basalis magnocellularis. Metcalf, R.H., Boegman, R.J. J. Neurochem. (1989) [Pubmed]
WikiGenes - Universities